To view this email as a web page, click here.
 
CLINICAL UPDATES
 
Pembro shows promising antitumor activity
Pembrolizumab (Keytruda) is showing encouraging antitumor activity in an ongoing phase II study including patients with high-risk, nonmuscle-invasive bladder cancer that is unresponsive to bacillus Calmette-Guérin treatment.
Learn more
ADVERTISEMENT
 
Video: Dr. Knudsen on how he obtains percutaneous access
Bodo Knudsen, MD, of The Ohio State University Wexner Medical Center, Columbus, explains his step-by-step process for obtaining percutaneous access in stone patients.
Watch the video
 
SURVEY
 
Is DRE still a relevant tool in the management of prostate cancer?
MORE FROM UROLOGY TIMES
 
AUA, ASTRO amend guideline for adjuvant and salvage RT after RP
Can 54640 and 49495-49525 be billed together?
JOB OPPORTUNITIES
 
NY-WNY Urology Associates
VT-University of Vermont
VT-University of Vermont
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.